Etanercept was effective and safe for ankylosing spondylitis

Bijlsma, Johannes
January 2003
ACP Journal Club;Jan/Feb2003, Vol. 138 Issue 1, p19
Academic Journal
Presents a study that investigated the effectiveness and safety of etanercept for ankylosing spondylitis. Assessment of the clinical characteristics of patients; Patient intervention; Outcome measures.


Related Articles

  • Arthritis Drug Gets A New Indication. Vernarec, Emil; Mangan, Doreen // RN;Sep2003, Vol. 66 Issue 9, p95 

    Reports on the U.S. Food and Drug Administration's approval of a drug for active ankylosing spondylitis. Mechanism of action; Recommended dose for adults; Drug efficacy.

  • Sulfasalazine.  // Reactions Weekly;2/6/2010, Issue 1287, p36 

    The article describes the case of a 33-year-old man who developed Mycobacteria avium complex (MAC) infection during long-term treatment for ankylosing spondylities.

  • ENBREL APPROVED FOR ANKYLOSING SPONDYLITIS. Dunkin, Mary Anne // Arthritis Today;Nov-Dec2003, Vol. 17 Issue 6, p43 

    Reports on the approval by the U.S. Food and Drug Administration of the use of etanercept Enbrel for people with alkylosing spondylitis, as of November 2003. Brief description of ankylosing spondylitis; Findings of a clinical trial of etanercept used in people with alkylosing spondylitis.

  • Ankylosing Spondylitis.  // Current Medical Literature: Rheumatology;2009, Vol. 28 Issue 3, p66 

    The article presents information on medical studies on ankylosing spondylitis(AS) published in medical journals as of August 2009. A study done by M. K. de Vries et al, determined the significant influence of immunogenicity in the treatment with etanercept patients with AS. The study showed that...

  • New Treatment for Spinal Disorder Proves Effective in UC San Francisco Study.  // Ascribe Newswire: Medicine;5/1/2002, p6 

    The pain and stiffness suffered by a quarter of a million people with the inflammatory spinal condition ankylosing spondylitis can be significantly relieved with a drug already approved for rheumatoid arthritis, according to results of a clinical trial. A study showed that 80 percent of patients...

  • Statement From Spondylitis Association Regarding Clinical Trial for Treatment of Spondylitis as Published in The New England Journal of Medicine.  // Ascribe Newswire: Medicine;5/1/2002, p15 

    The Spondylitis Association of America (SAA) is encouraged by a successful clinical trial showing that the drug enbrel provides relief for patients suffering from ankylosing spondylitis. The SAA estimates that at least 300,000 and likely one million people in the U.S. suffer from the disease,...

  • Merck withdraws Arcoxia NDA for now.  // Medical Marketing & Media;May2002, Vol. 37 Issue 5, p38 

    Reports the withdrawal of a new drug application (NDA) for Arcoxia by Merck in the U.S. Plans for the resubmission of an efficacy data to support indication for ankylosing spondylitis; Clinical manifestations of the disease; Indications presented in the original NDA submitted by Merck.

  • Etanercept.  // Reactions Weekly;8/1/2013, Issue 1463, p19 

    The article presents a case study of a 20-year-old man who experienced exacerbation of verruca vulgaris, while being treated for ankylosing spondylitis with etanercept.

  • NEW HELP for Ankylosing Spondylitis. Mann, Denise; Siegfried, Donna Rae // Arthritis Today;Nov/Dec2005, Vol. 19 Issue 6, p70 

    Reports on a study exploring the use of the pamidronate drug for ankylosing spondylitis (AS), as of November 2005. Background on the incidence of osteoporosis in patients with AS; Information on a COX-2 drug approved by the U.S. Food and Drug Administration for the treatment of pain, stiffness...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics